Boston Pharma's Efimosfermin Alfa Shows Strong Phase II Results for Monthly MASH Treatment Amid Growing Competition

Boston Pharmaceuticals has shared encouraging results from its Phase II trial of efimosfermin alfa, a once-monthly injection designed to treat metabolic dysfunction-associated steatohepatitis (MASH). The study findings highlight that 45.2% of patients who received efimosfermin alfa experienced significant improvement in fibrosis, without worsening MASH, compared to only 20.6% in the placebo group[1][2]. Furthermore, the treatment resulted in MASH resolution in 67.7% of its recipients versus 29.4% for placebo, showcasing a marked statistically significant effect[1]. With a favorable safety profile and minimal side effects reported, efimosfermin alfa's monthly dosing schedule offers a competitive advantage over other FGF21 analogues, which require weekly dosing[1][2]. Boston Pharmaceuticals plans to utilize these results in continuing their Phase II trials through an open-label extension and in future regulatory discussions[1].